Search the Newsreel

Mistras Group Inc expected to post earnings of 24 cents a share - Earnings Preview

Mistras Group Inc (MG) is projected to report earnings of 24 cents per share. This information is part of an earnings preview, likely indicating an upcoming financial disclosure. The full article is available to subscribers of TradingView, which aggregates content from sources like Reuters.

Sei Investments Co. Has $3.03 Million Stock Holdings in Mistras Group Inc $MG

Sei Investments Co. significantly increased its stake in Mistras Group Inc. by 249.4% in the first quarter, now holding 204,840 shares valued at approximately $3.03 million. Other institutional investors have also adjusted their positions, with overall institutional ownership at 74.92%. Analysts currently have a …

Mistras Group (MG) Q1 2026 Earnings: EPS Surges Past Estimates, Stock Gains 2.81% - Estimate Dispersion

Milestone Pharmaceuticals (MIST): Pavaki Capital group reports 7.3% ownership stake

Pavaki Capital Partners, LP, along with Pavaki Capital Management, LLC and Ashok Rambhai Patel, has reported a 7.3% beneficial ownership stake in Milestone Pharmaceuticals Inc. This ownership, totaling 9,067,848 common shares, was effective as of December 31, 2025. The group holds shared voting and …

Mistras Group, Inc. (MG) Latest Stock News & Headlines

This article provides the latest stock news and headlines for Mistras Group, Inc. (MG), including its current stock price and recent news releases. It also features a performance overview, comparing MG's trailing total returns against the S&P 500, showing significant outperformance year-to-date, and over …

Lazard Asset Management LLC Invests $1.04 Million in Mistras Group Inc $MG

Lazard Asset Management LLC has acquired a new stake of 70,369 shares, valued at $1.04 million, in Mistras Group Inc (NYSE:MG) during the first quarter. This makes Lazard Asset Management LLC the owner of approximately 0.22% of Mistras Group. Other institutional investors have also …

Milestone Pharmaceuticals (MIST) Expected to Announce Earnings on Wednesday

Milestone Pharmaceuticals (MIST) is set to announce its Q2 2026 earnings before market open on Wednesday, August 12th. Analysts project a loss of $0.18 per share on revenue of $817,000, following a previous quarter that significantly missed expectations. The stock is trading near its …

Board Change and Q2 Results Could Be A Game Changer For Mettler-Toledo International (MTD)

Mettler-Toledo International Inc. recently reported second-quarter 2026 results showing higher sales of US$1,027.31 million and net income of US$232.90 million, while also appointing MISTRAS Group CEO Natalia Shuman to its Board of Directors effective 3 August 2026. Together with Baron Capital's decision to increase …

Milestone Pharmaceuticals sets Aug. 12, 8:30 a.m. webcast

Milestone Pharmaceuticals (Nasdaq: MIST) announced it will report its second-quarter 2026 financial results on Wednesday, August 12, 2026, before market open. The company will host an investor conference call and webcast at 8:30 AM ET on the same day, with a replay available afterward. …

Milestone Pharmaceuticals to report Q2 2026 financial results on August 12 with investor call.

Milestone Pharmaceuticals Inc. announced it will release its financial results for the second quarter ending June 30, 2026, on August 12 before the market opens. The company, which specializes in cardiovascular medicines and has an FDA-approved nasal spray, will also host a conference call …

Natalia Shuman Joins Mettler Toledo Board of Directors

COLUMBUS, Ohio, August 03, 2026--(BUSINESS WIRE)--Mettler-Toledo International Inc. (NYSE: MTD) announced today that Natalia Shuman has been appointed to its Board of Directors effective August 3, 2026. Ms. Shuman has served as President and Chief Executive Officer of MISTRAS Group, a global leader in …

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Milestone Pharmaceuticals (NASDAQ:MIST) has received a "Moderate Buy" consensus rating from six analysts, with an average 12-month price target of $7.25. Institutional investors hold a significant 86.18% stake in the company, with many increasing or initiating positions. Despite the positive analyst outlook, MIST shares …

Mistras Group Inc (MG) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Mistras Group Inc (MG), stating its current risk score is 4.22, ranking 73rd out of 96 in the Oil & Gas industry. It highlights the company's beta of 0.89, indicating lower volatility compared to the S&P 500, …

MG|Mistras Group Inc|Price:15.020|Chg%:-0.370

This article provides a comprehensive analysis of Mistras Group Inc (MG) using TradingKey's stock score system. It highlights that MG has relatively healthy fundamentals and significant growth potential, although its valuation is considered fairly valued within the Oil & Gas industry. The stock has …

Mistras Group Inc (MG) Financial Health: Profitability & Balance Sheet Analysis

Mistras Group Inc (MG) currently holds a financial score of 6.52, ranking 71 out of 96 in the Oil & Gas industry, indicating stable financial status and average operating efficiency. The company's latest quarterly revenue was $169.03 million, marking a 4.59% year-over-year increase, while …

Mistras Group Inc (MG) Institutional Confidence

Mistras Group Inc (MG) has an institutional shareholding score of 5.00, ranking 43rd out of 96 in the Oil & Gas industry. The institutional shareholding proportion is 63.53%, showing a 9.03% increase quarter-over-quarter. Chuck Royce is the largest institutional shareholder with 1.27 million shares, …

MISTRAS Group Announces Conference Call to Discuss Second Quarter Results on August 11, 2026

MISTRAS Group, Inc. has scheduled a conference call for Tuesday, August 11, 2026, at 9:00 a.m. EDT to discuss its second-quarter 2026 financial results. A press release detailing these results will be issued after the market closes on Monday, August 10, 2026. Interested parties …

MISTRAS Group to Release Second-Quarter Results Aug. 10

MISTRAS Group (NYSE: MG) will host a conference call on Tuesday, August 11, 2026, at 9:00 a.m. Eastern Time to discuss its second-quarter 2026 results. The earnings press release will be issued after market close on Monday, August 10, 2026. Investors can access a …

Mistras Group (MG) Projected to Release Quarterly Earnings on Tuesday

Mistras Group Inc (MG) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Mistras Group Inc (MG) stock information, focusing on its dividends and stock splits. It notes that the company has distributed $0.00 in dividends over the past five years, indicating no recent dividend payouts. The article also includes current …

Milestone Pharmaceuticals Inc (MIST) Valuation: PE, PB & Fair Value Analysis

Milestone Pharmaceuticals Inc (MIST) currently holds a valuation score of 6.03, placing it 355th out of 385 in the Biotechnology & Medical Research industry. Its P/E ratio stands at -1.68, which is significantly below its recent high and above its recent low. The company …

Milestone Pharmaceuticals Inc (MIST) Cash Flow

This article provides a detailed quarterly and annual cash flow statement for Milestone Pharmaceuticals Inc (MIST), allowing users to evaluate its financial health. It includes data on operating, investing, and financing cash flows, along with frequently asked questions defining these terms and specific figures …

Milestone Pharmaceuticals Inc (MIST) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides a dividend and stock split history for Milestone Pharmaceuticals Inc (MIST). It indicates that the company has distributed a total of $0.00 USD in dividends over the past five years, with no specific dividend data currently available. The page also presents …

MIST|Milestone Pharmaceuticals Inc|Price:1.060|Chg%:-0.070

Milestone Pharmaceuticals Inc. (MIST) shows relatively healthy fundamentals and high growth potential, despite a weak short-term stock market performance. The company is considered fairly valued and has very high institutional ownership, with analysts rating it as an overall "Buy" and a significant upside potential. …

Mistras Group Inc (MG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Mistras Group Inc (MG), categorizing its revenue by business segments and geographical regions. As of April 6, the company's largest business segment is Oil Gas, contributing 54.81% of total revenue, while the United States accounts for …

Mistras Group Inc Q1 2026 Earnings: EPS Beat Lifts Profitability, Yet Stock Slips - Profitability Analysis

Mistras Group Inc Q1 2026 Earnings: EPS Beat Lifts Profitability, Yet Stock Slips - Fiscal Year Earnings

Milestone Pharmaceuticals Inc. Revenue Breakdown – NASDAQ:MIST

Milestone Pharmaceuticals Inc. (NASDAQ: MIST) generated $1.55 million USD in revenue last year, primarily from its Cardiovascular Medicines segment. Canada was the main contributor to this revenue, also accounting for $1.55 million USD. This represents an increase from the previous year's $1.00 million USD …

Milestone Pharmaceuticals Inc (MIST) Institutional Confidence

Milestone Pharmaceuticals Inc (MIST) has an institutional shareholding score of 3.00, placing it 192nd out of 386 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 25.86%, marking a 48.38% quarter-over-quarter decrease. Steven Cohen is the largest institutional shareholder, holding …

MISTRAS expands Los Angeles lab with aerospace manufacturing services

MISTRAS Group has expanded its Los Angeles laboratory by adding new services and equipment for aerospace and defense manufacturing. The facility now offers welding, grinding, and rework services, along with advanced CNC machines and automated ultrasonic testing systems. This expansion aims to simplify complex …

MISTRAS Group Continues Strategic Investments in Aerospace & Defense Market with Expansion of its Los Angeles, California Lab

MISTRAS Group (NYSE: MG) has expanded the capabilities of its Los Angeles, CA laboratory, aiming to support the strong demand and production backlogs in the commercial and military aerospace & defense market. The enhancements include new equipment and services such as welding, grinding, rework, …

Wells Fargo Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Cuts Target Price to $7

Wells Fargo has reiterated its Buy rating for Milestone Pharmaceuticals (MIST.US) but has adjusted its price target down to $7. This indicates that while the firm still sees long-term potential for the company, it has revised its valuation expectations.

MISTRAS Lab Adds Machines for Aerospace Parts Up to 3 Tons

MISTRAS Group (NYSE: MG) has expanded the capabilities of its Los Angeles, California lab to better support commercial and military aerospace and defense manufacturers. The upgrades include new welding, grinding, and rework services, two CNC machines capable of handling parts up to 3 tons, …

Mistras Group (MG) Corporate presentation Summary

Mistras Group (MG) presented a corporate summary outlining its global leadership in technology-enabled asset integrity and testing solutions, with a focus on delivering innovative, data-driven solutions across diverse industries. The company reported $724 million in revenue for 2025, with guidance of $730–$750 million for …

Milestone Pharmaceuticals (MIST) Q4 2024 earnings summary

Milestone Pharmaceuticals provided a summary of its Q4 2024 earnings, highlighting its financial position and upcoming milestones. The company is awaiting FDA approval for CARDAMYST nasal spray for PSVT, with a targeted commercial launch in mid-2025, and plans to initiate a Phase 3 trial …

MISTRAS Launches AEScout to Help Industrial Operators Detect Active Damage and Make Data-Driven Integrity Decisions

MISTRAS Group, Inc. has launched AEScout, an acoustic emission (AE) monitoring solution designed for rapid deployment. This technology helps industrial operators identify active damage mechanisms like cracking and corrosion, enabling more informed asset integrity decisions between traditional inspection intervals. AEScout is particularly effective in …